{"id":2632,"date":"2024-01-11T12:39:47","date_gmt":"2024-01-11T09:39:47","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=2632"},"modified":"2024-01-11T12:41:56","modified_gmt":"2024-01-11T09:41:56","slug":"hasta-yolculugunu-iyilestirmeyi-hedefleyen-projelere-imza-atiyoruz","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=2632","title":{"rendered":"Hasta Yolculu\u011funu \u0130yile\u015ftirmeyi Hedefleyen Projelere \u0130mza At\u0131yoruz"},"content":{"rendered":"\n

T\u00fcrkiye\u2019de 65 y\u0131ldan fazla s\u00fcredir \u00f6zellikli tedaviler, genel ila\u00e7lar, a\u015f\u0131lar ve t\u00fcketici sa\u011fl\u0131\u011f\u0131 alanlar\u0131nda halk sa\u011fl\u0131\u011f\u0131 i\u00e7in \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcren Sanofi\u2019nin Kurumsal \u0130li\u015fkiler ve Pazara Eri\u015fim Direkt\u00f6r\u00fc G\u00fcray Karacar, \u00fclkemizde yenilik\u00e7i ila\u00e7lar\u0131n pazar eri\u015fim s\u00fcre\u00e7leri, Sanofi\u2019nin projeleri, inovasyona bak\u0131\u015f a\u00e7\u0131s\u0131 ve 2024 y\u0131l\u0131 planlar\u0131na ili\u015fkin sorular\u0131m\u0131z\u0131 yan\u0131tlad\u0131.<\/strong><\/p>\n\n\n\n

G\u00fcray Karacar<\/strong><\/p>\n\n\n\n

Sanofi T\u00fcrkiye Kurumsal \u0130li\u015fkiler ve Pazara Eri\u015fim Direkt\u00f6r\u00fc<\/strong><\/p>\n\n\n\n

Sanofi\u2019nin T\u00fcrkiye\u2019deki faaliyetlerinden k\u0131saca bahseder misiniz? Sanofi T\u00fcrkiye Kurumsal \u0130li\u015fkiler & Pazar Eri\u015fim Departman\u0131 olarak \u00e7al\u0131\u015fma alanlar\u0131n\u0131z nedir?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Sanofi olarak T\u00fcrkiye\u2019deki 65 y\u0131l\u0131 a\u015fan ayak izimizle \u00f6zellikli tedaviler, genel ila\u00e7lar, a\u015f\u0131lar ve t\u00fcketici sa\u011fl\u0131\u011f\u0131 alanlar\u0131nda halk sa\u011fl\u0131\u011f\u0131 i\u00e7in \u00e7al\u0131\u015fmalar\u0131m\u0131z\u0131 s\u00fcrd\u00fcr\u00fcyoruz. Kurumsal ili\u015fkiler ve pazar eri\u015fim ekibi olarak, uzun y\u0131llara dayanan k\u00fcresel tecr\u00fcbemizle insan\u0131 oda\u011f\u0131m\u0131za al\u0131yor, hastalar\u0131n tedavilere eri\u015fimini kesintisiz \u015fekilde sa\u011flayarak hasta yolculu\u011funu iyile\u015ftirme hedefiyle projelere imza at\u0131yoruz. Bunun yan\u0131 s\u0131ra, sa\u011fl\u0131k alan\u0131nda kamu politikalar\u0131n\u0131n geli\u015ftirilmesini destekleyecek \u00e7al\u0131\u015fmalar ve projeler y\u00fcr\u00fct\u00fcyoruz.<\/p>\n\n\n\n

\u00dclkemizdeki ila\u00e7lar\u0131n pazar eri\u015fim s\u00fcre\u00e7lerini de\u011ferlendi\u011finizde T\u00fcrkiye\u2019deki genel durumu AB \u00fclkeleri ile nas\u0131l k\u0131yaslars\u0131n\u0131z?<\/strong><\/p>\n\n\n\n

Sekt\u00f6r\u00fcm\u00fczde pazara eri\u015fim s\u00fcre\u00e7leri, bir ilac\u0131n ruhsatland\u0131rma a\u015famas\u0131ndan sonraki fiyatland\u0131rma, geri \u00f6deme ve pazara arz edilmeyi i\u00e7eriyor. D\u00fcnya genelinde oldu\u011fu gibi T\u00fcrkiye\u2019de de sa\u011fl\u0131k harcamalar\u0131 ya\u015flanan n\u00fcfus, ya\u015fam s\u00fcresinin uzamas\u0131 ve kronik hastal\u0131klardaki art\u0131\u015f gibi sebeplerle her y\u0131l y\u00fckseli\u015f g\u00f6steriyor.<\/p>\n\n\n\n

TU\u0130K\u2019in a\u00e7\u0131klad\u0131\u011f\u0131 son rakamlara g\u00f6re ki\u015fi ba\u015f\u0131na d\u00fc\u015fen sa\u011fl\u0131k harcamas\u0131 2021’de 4 bin 206 lira iken, 2022’de y\u00fczde 69,8 artarak 7 bin 141 liraya y\u00fckseldi\u011fini g\u00f6r\u00fcyoruz. \u00d6te yandan \u00fclkemizde hastalar\u0131n eri\u015fimine sunulan ila\u00e7lar\u0131n de\u011fer baz\u0131nda y\u00fczde 94\u2019\u00fc geri \u00f6deme kapsam\u0131nda olmas\u0131na ra\u011fmen, ila\u00e7 harcamalar\u0131n\u0131n GSY\u0130H\u2019ye oran\u0131 uzun y\u0131llardan beri y\u00fczde 1\u2019in alt\u0131nda kal\u0131yor.<\/p>\n\n\n\n

Avrupa \u0130la\u00e7 Sanayii Dernekleri Federasyonu\u2019nun (EFPIA) 2023\u2019de yay\u0131mlad\u0131\u011f\u0131 \u2018W.A.I.T (Hastalar Yenilik\u00e7i Tedavilere Eri\u015fimi Beklerken) Raporu\u2019na g\u00f6re, 2018-2021 y\u0131llar\u0131 aras\u0131nda T\u00fcrkiye\u2019de hastalara sunulan yenilik\u00e7i ila\u00e7lar\u0131n say\u0131s\u0131n\u0131n<\/p>\n\n\n\n

 Avrupa \u00fclkelerine k\u0131yasla olduk\u00e7a s\u0131n\u0131rl\u0131 oldu\u011fu g\u00f6r\u00fcl\u00fcyor. AB \u00fclkelerinde hastalar\u0131n ila\u00e7lara ortalama eri\u015filebilirlik d\u00fczeyi y\u00fczde 45 iken T\u00fcrkiye\u2019de sadece y\u00fczde 4. Bu do\u011frultuda AB \u00fclkelerinde ya\u015fayan vatanda\u015flara k\u0131yasla T\u00fcrkiye\u2019de yenilik\u00e7i ila\u00e7lardan daha az ki\u015finin faydaland\u0131\u011f\u0131n\u0131 g\u00f6rebiliyoruz. Bu da \u00fclkemizde yenilik\u00e7i ila\u00e7lara hastalar\u0131n eri\u015fimini s\u00fcrd\u00fcr\u00fclebilir k\u0131lmak i\u00e7in finansman imk\u00e2nlar\u0131n\u0131n de\u011ferlendirilmesinin ve yenilik\u00e7i ilaca eri\u015fim ile ilgili dengeli ve s\u00fcrd\u00fcr\u00fclebilir politikalara yer verilmesinin \u00f6nemini ortaya koyuyor.<\/p>\n\n\n\n

Bunun yan\u0131 s\u0131ra, geri \u00f6deme a\u015famas\u0131nda ise di\u011fer \u00f6rnek Avrupa \u00fclkelerine benzer \u015fekilde, geri \u00f6deme kararlar\u0131n\u0131n hasta odakl\u0131 ve yenilik\u00e7i ilac\u0131n sundu\u011fu temel ilave fayda ve de\u011feri dikkate al\u0131narak belirlenmesi b\u00fcy\u00fck \u00f6nem arz ediyor.<\/p>\n\n\n\n

Sanofi\u2019nin payda\u015flar\u0131 kimlerdir? Birlikte \u00e7al\u0131\u015ft\u0131\u011f\u0131n\u0131z payda\u015flar\u0131n\u0131z ile ne gibi faaliyetler y\u00fcr\u00fct\u00fcyorsunuz, neler yap\u0131yorsunuz?<\/strong><\/p>\n\n\n\n

Halk sa\u011fl\u0131\u011f\u0131 ad\u0131na geli\u015ftirdi\u011fimiz t\u00fcm proje ve programlarda, sa\u011fl\u0131k otoritesi, sa\u011fl\u0131k profesyonelleri, sivil toplum \u00f6rg\u00fctleri ve \u00f6zel sekt\u00f6rden olu\u015fan \u00e7ok \u00e7e\u015fitli bir payda\u015f grubu ile birlikte \u00e7al\u0131\u015f\u0131yoruz. Temel amac\u0131m\u0131z olan hastal\u0131klardaki fark\u0131ndal\u0131\u011f\u0131 artt\u0131rman\u0131n yan\u0131 s\u0131ra, bilimsel ortakl\u0131klarla da hastay\u0131 merkezine alan, hasta yolculu\u011funu iyile\u015ftirmeyi hedefleyen projelere destek veriyoruz.<\/p>\n\n\n\n

Projelerimizle destek verdi\u011fimiz konu ba\u015fl\u0131klar\u0131ndan biri olduk\u00e7a uzun bir tan\u0131 s\u00fcrecine sahip olan nadir hastal\u0131klar alan\u0131nda. Ad\u0131 \u2018nadir\u2019 olarak ge\u00e7mesine ra\u011fmen bu hastal\u0131klar\u0131n bug\u00fcn, d\u00fcnyada 350 milyonu, T\u00fcrkiye\u2019de ise 6 milyon insan\u0131 etkiledi\u011fi tahmin ediliyor. Tan\u0131 s\u00fcreci de uzun s\u00fcrerek nadir hastal\u0131klarla ki\u015filerin do\u011fru te\u015fhise\u202fula\u015fmas\u0131 maalesef 7 y\u0131l alabiliyor ve bu s\u00fcre\u00e7te hastalar\u0131n farkl\u0131 bran\u015ftan doktorlar\u0131 ziyaret etmesi gerekebiliyor. Bunun yan\u0131 s\u0131ra, nadir hastal\u0131klarda hastalar\u0131n yakla\u015f\u0131k y\u00fczde 50\u2019sini \u00e7ocuklar olu\u015fturuyor ve bu hastal\u0131\u011fa sahip \u00e7ocuklar\u0131n y\u00fczde 30\u2019u maalesef 5 ya\u015f\u0131n\u0131 g\u00f6remiyor. Nadir hastal\u0131klarda ortaya \u00e7\u0131kan sonu\u00e7lar hem hasta olan birey, hem ailesi, hem de toplum a\u00e7\u0131s\u0131ndan \u00e7ok a\u011f\u0131r olabiliyor.<\/p>\n\n\n\n

Ayr\u0131ca nadir hastal\u0131klara sahip bireylerin do\u011fru merkezlere ula\u015fmas\u0131ndaki gecikme\u202fve\u202f tan\u0131 i\u00e7in gerekli teknik ve laboratuvar hizmetlerinin yetersizli\u011fi\u202fgibi durumlar, tan\u0131 s\u00fcrecinde zorluklar\u202fyaratarak s\u00fcrecin uzamas\u0131na da neden oluyor. Biz de bu ama\u00e7la lizozomal depo hastal\u0131klar\u0131 alan\u0131nda modern tan\u0131 ve tedavi y\u00f6ntemlerine y\u00f6nelik ara\u015ft\u0131rmalar yapmak \u00fczere Ankara \u00dcniversitesi ile i\u015f birli\u011fi yaparak Nadir Hastal\u0131klar Uygulama ve Ara\u015ft\u0131rma Merkezi NAD\u0130R\u2019in \u00e7al\u0131\u015fmalar\u0131na bilimsel destek sa\u011fl\u0131yoruz. Buradaki amac\u0131m\u0131z; nadir hastal\u0131klar\u0131n te\u015fhisi, tedavisi, multidisipliner hasta takibi, klinik ara\u015ft\u0131rmalar ve kay\u0131t \u00e7al\u0131\u015fmalar\u0131n\u0131n y\u00fcr\u00fct\u00fclmesi i\u00e7in NAD\u0130R\u2019in bilimsel faaliyetlerin g\u00fc\u00e7lendirilmesi oldu. Ayr\u0131ca bu i\u015f birli\u011fimiz kapsam\u0131nda merkez b\u00fcnyesinde, g\u00f6revli akademisyenlere bilimsel ara\u015ft\u0131rmalar yapma \u015fans\u0131 sunarak veri \u00fcretmek ve yeni teknolojiler geli\u015ftirmek i\u00e7in rehberlik deste\u011fi verece\u011fiz.<\/p>\n\n\n\n

Bu alandaki bir di\u011fer \u00e7al\u0131\u015fmam\u0131z da Kas\u0131m 2022\u2019de, \u0130STMEM (\u0130stanbul \u0130l Milli E\u011fitim M\u00fcd\u00fcrl\u00fc\u011f\u00fc) ile Narin \u00c7ocuklar Projesi kapsam\u0131nda imzalad\u0131\u011f\u0131m\u0131z i\u015f birli\u011fi anla\u015fmas\u0131 oldu.  Bu i\u015f birli\u011fiyle de nadir hastal\u0131klarla m\u00fccadele eden \u00e7ocuk hastalar\u0131n e\u011fitim hayatlar\u0131nda ya\u015fad\u0131klar\u0131 sorunlar\u0131 g\u00f6r\u00fcn\u00fcr hale getirmeyi, hastal\u0131klar hakk\u0131nda \u00f6\u011fretmenlerin fark\u0131ndal\u0131\u011f\u0131n\u0131 art\u0131r\u0131p zorluklara t\u00fcm payda\u015flar\u0131n katk\u0131s\u0131 ile \u00e7\u00f6z\u00fcmler geli\u015ftirebilmek i\u00e7in bu \u00e7ocuklara do\u011fru ilk yakla\u015f\u0131m ve sorumluluk s\u0131n\u0131rlar\u0131 konusunda akademik bilgilendirilme yap\u0131lmas\u0131n\u0131, temel ve \u00f6zel ihtiya\u00e7lar\u0131na eri\u015fimlerinin kolayla\u015ft\u0131r\u0131lmas\u0131 ve e\u011fitim hayatlar\u0131n\u0131n uyum i\u00e7inde devaml\u0131l\u0131\u011f\u0131n\u0131n sa\u011flanmas\u0131na y\u00f6nelik faydalar elde etmeyi ama\u00e7l\u0131yoruz.<\/p>\n\n\n\n

Bir di\u011fer odak noktam\u0131z ise diyabet hastal\u0131\u011f\u0131. Bug\u00fcn diyabet 21. y\u00fczy\u0131l\u0131n en b\u00fcy\u00fck k\u00fcresel sa\u011fl\u0131k sorunlar\u0131ndan biri olarak g\u00f6r\u00fclmekte. Diyabet belirti g\u00f6stermeden uzun y\u0131llar varl\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrebilen, sinsice ilerleyen bir hastal\u0131k. Bu y\u00fczden de diyabetle ya\u015fayan bireylerin yakla\u015f\u0131k yar\u0131s\u0131n\u0131n hastal\u0131\u011f\u0131n\u0131n fark\u0131nda olmad\u0131\u011f\u0131 tahmin ediliyor. Bu do\u011frultuda bireysel fark\u0131ndal\u0131k ve d\u00fczenli kontrol\u00fcn olduk\u00e7a kritik oldu\u011fu bu hastal\u0131k i\u00e7in biz de Sanofi olarak \u00fcst\u00fcm\u00fcze d\u00fc\u015feni yap\u0131yor, fark\u0131ndal\u0131k \u00e7al\u0131\u015fmalar\u0131m\u0131z ile diyabetin toplumsal etkisini en aza indirmeyi hedefliyoruz.<\/p>\n\n\n\n

Bu alandaki en \u00f6nemli projemiz hi\u00e7 ku\u015fkusuz Mill\u00ee E\u011fitim Bakanl\u0131\u011f\u0131, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ve \u00c7ocuk Endokrinoloji ve Diyabet Derne\u011fi i\u015f birli\u011fi ve Sanofi\u2019nin ko\u015fulsuz deste\u011fi ile 2010 y\u0131l\u0131nda hayata ge\u00e7en \u2018Okulda Diyabet Program\u0131\u2019. Program ile okullarda tip 1 diyabetin erken tan\u0131s\u0131na destek olmak, diyabet fark\u0131ndal\u0131\u011f\u0131n\u0131 art\u0131rmak ve diyabetli \u00e7ocuklar\u0131n okuldaki ya\u015fam kalitelerini y\u00fckseltmeyi ama\u00e7l\u0131yoruz. Tip 1 diyabetli \u00f6\u011frencilerin okulda tedavilerinin kesintisiz olarak devam edebilmesi ve kendi akranlar\u0131 gibi b\u00fct\u00fcn okul aktivitelerine kat\u0131lmalar\u0131n\u0131n sa\u011flanabilmesi i\u00e7in b\u00fct\u00fcn okul \u00e7al\u0131\u015fanlar\u0131n\u0131n bu konudaki kat\u0131l\u0131m\u0131n\u0131n ve deste\u011finin \u00e7ok \u00f6nemli oldu\u011funu biliyoruz.<\/p>\n\n\n\n

Program kapsam\u0131nda bug\u00fcne kadar 60 bin okul, 585 bin \u00f6\u011fretmen, 580 bin veli ve 7,5 milyon \u00f6\u011frenciye ula\u015ft\u0131k. Program kapsam\u0131nda 2020 y\u0131l\u0131nda \u2018Tip 1 Diyabetli \u00d6\u011frencilerin Okullarda Bak\u0131m\u0131 ve Desteklenmesi Hakk\u0131nda Y\u00f6nerge\u2019 yay\u0131nland\u0131.<\/p>\n\n\n\n

Bunun yan\u0131 s\u0131ra, program\u0131n en \u00f6nemli \u00e7\u0131kt\u0131lar\u0131ndan birinin de tip 1 diyabetli \u00f6\u011frencilerin ya\u015f\u0131tlar\u0131ndan daha s\u0131k tuvalete gitme, ara \u00f6\u011f\u00fcn alma gibi ihtiya\u00e7lar\u0131 i\u00e7in kritik \u00f6nem arz eden okullardaki Kantin Y\u00f6netmeli\u011fi (\u015feker oran\u0131 y\u00fcksek \u00fcr\u00fcnlerin sat\u0131lmas\u0131n\u0131n yasaklanmas\u0131) ve S\u0131nav Y\u00f6netmeli\u011fi\u2019nin diyabetli \u00e7ocuklar lehine de\u011fi\u015ftirilmesi oldu\u011funu s\u00f6yleyebiliriz.<\/p>\n\n\n\n

Ge\u00e7ti\u011fimiz y\u0131l program kapsam\u0131nda \u00f6nemli bir ad\u0131m daha atarak, diyabet bilincini toplumda \u00e7ok daha geni\u015f kitlelere yaymak \u00fczere tamamen Mill\u00ee E\u011fitim Bakanl\u0131\u011f\u0131 sistemine entegre olarak Okulda Diyabet Program\u0131 E\u011fitim Platformu\u2019nun a\u00e7\u0131lmas\u0131na ko\u015fulsuz katk\u0131 sa\u011flad\u0131k. Platform, diyabetli \u00e7ocuklar\u0131n okulda g\u00fcvenli \u015fekilde zaman ge\u00e7irmeleri ve ba\u015fta \u00f6\u011fretmenler olmak \u00fczere t\u00fcm okul \u00e7al\u0131\u015fanlar\u0131na e\u011fitim vermeyi ama\u00e7lamakta. \u00d6zellikle okullar\u0131nda tip 1 diyabetli \u00f6\u011frenci olan \u00f6\u011fretmenlerin ve t\u00fcm okul personelinin e\u011fitim mod\u00fcl\u00fcn\u00fc tamamlamas\u0131 gerekiyor. Platformu bir y\u0131lda yakla\u015f\u0131k 400 bin ki\u015fi ziyaret etti, yakla\u015f\u0131k 50 bin okul personeli ise e\u011fitim mod\u00fcllerini tamamlayarak sertifika almaya hak kazand\u0131.<\/p>\n\n\n\n

Son olarak, \u00c7EHAD (\u00c7ocuk Enfeksiyon Hastal\u0131klar\u0131 Derne\u011fi) ile ortakla\u015fa y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz A\u015f\u0131ya G\u00fcven inisiyatifi ile de \u00f6zellikle Covid-19 pandemisi sonras\u0131 halk aras\u0131nda artan a\u015f\u0131 teredd\u00fct\u00fcn\u00fc giderebilmek ve toplum sa\u011fl\u0131\u011f\u0131n\u0131 tehdit eden t\u00fcm bula\u015f\u0131c\u0131 hastal\u0131klara kar\u015f\u0131 \u00fclkemizde a\u015f\u0131lanma oranlar\u0131n\u0131 art\u0131rabilmeyi hedefliyoruz. Bu kapsamda da a\u015f\u0131lanma oranlar\u0131n\u0131n daha d\u00fc\u015f\u00fck seyretti\u011fi pilot illerde halk\u0131n sa\u011fl\u0131k okuryazarl\u0131\u011f\u0131n\u0131n ve a\u015f\u0131 bilincinin geli\u015ftirilmesi i\u00e7in ailelere y\u00f6nelik il seminerleri ba\u015flatt\u0131k.<\/p>\n\n\n\n

Sa\u011fl\u0131k end\u00fcstrisinde bir\u00e7ok alanda inovasyona \u015fahit oluyoruz. Sanofi T\u00fcrkiye, inovasyona nas\u0131l destek veriyor?<\/strong><\/p>\n\n\n

\n
\"\"
Sanofi T\u00fcrkiye Kurumsal \u0130li\u015fkiler ve Pazara Eri\u015fim Departman\u0131<\/strong><\/figcaption><\/figure><\/div>\n\n\n

Dijital d\u00f6n\u00fc\u015f\u00fcm sa\u011fl\u0131k alan\u0131nda te\u015fhis ve erken tan\u0131, tedavi planlamas\u0131 ve ki\u015fiselle\u015ftirilmi\u015f bak\u0131m, ila\u00e7 ke\u015ffi ve geli\u015ftirme, hasta takibi ve evden bak\u0131m alanlar\u0131nda sa\u011fl\u0131k sisteminin daha verimli hale getirilmesi a\u00e7\u0131s\u0131ndan ciddi f\u0131rsatlar yarat\u0131yor. Bu noktada biz de inovasyona katk\u0131 sa\u011flayacak projeleri desteklemeye \u00f6zen g\u00f6steriyoruz. \u00d6rne\u011fin; PharmUp\u2019la birlikte \u00fclkemizde yeni geli\u015fmekte olan inovasyon ekosistemine katk\u0131 sunmay\u0131 hedefliyoruz. 2019 y\u0131l\u0131nda hayata ge\u00e7irdi\u011fimiz ve Endeavour ile birlikte y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz PharmUp Giri\u015fimcilik Program\u0131 ile sa\u011fl\u0131k sekt\u00f6r\u00fcne y\u00f6nelik \u00e7\u00f6z\u00fcmler geli\u015ftirebilecek her alandan ve sekt\u00f6rden giri\u015fimciyi 4 y\u0131ld\u0131r ba\u015far\u0131yla bir araya getiriyoruz.\u202f<\/p>\n\n\n\n

2022 y\u0131l\u0131nda ise PharmUp\u2019\u0131 \u00e7ok payda\u015fl\u0131 bir platforma d\u00f6n\u00fc\u015ft\u00fcrerek giri\u015fimcilerin \u00fcr\u00fcn geli\u015ftirmeden pazara sunmalar\u0131na kadar t\u00fcm yolculuklar\u0131nda ihtiya\u00e7lar\u0131na uygun \u00e7\u00f6z\u00fcmler \u00fcretmesini ama\u00e7lad\u0131k. Bu T\u00fcrkiye merkezli \u00e7ok payda\u015fl\u0131 giri\u015fimcilik platformu kapsam\u0131nda, Ba\u015fak\u015fehir Living Lab, Teknopark \u0130stanbul ve Lokman Hekim \u00dcniversitesi Sa\u011fl\u0131k ve \u0130la\u00e7 Teknoloji Merkezi (LHUSTEK) ve TT Ventures ile \u00e7e\u015fitli i\u015f birliklerine imza att\u0131k. <\/p>\n\n\n\n

Ayr\u0131ca PharmUp platformunun bu seneki tematik projesi Care4RARE program\u0131n\u0131 ba\u015flatt\u0131\u011f\u0131m\u0131z\u0131 duyurmak isterim. Program kapsam\u0131nda, nadir hastal\u0131klar alan\u0131nda \u00e7\u00f6z\u00fcm sunan giri\u015fimcilere y\u00f6nelik a\u00e7\u0131lacak olan \u00e7a\u011fr\u0131ya ba\u015fvuru yapan giri\u015fimciler ve \u00e7\u00f6z\u00fcmleri desteklemeyi hedefliyoruz.<\/p>\n\n\n\n

2024 y\u0131l\u0131nda Sanofi\u2019nin yol haritas\u0131nda yer alan en \u00f6nemli maddeler neler? <\/strong><\/p>\n\n\n\n

\u00c7al\u0131\u015fma stratejilerimizi hastalar\u0131n kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7lar\u0131na \u00e7\u00f6z\u00fcm geli\u015ftirmek \u00fczere kurguluyoruz. Bu sene duyurdu\u011fumuz Hasta ve Hasta Topluluklar\u0131na Taahh\u00fcd\u00fcm\u00fcz ise bunun bir kan\u0131t\u0131. D\u00f6rt temel alanda in\u015fa etti\u011fimiz taahh\u00fcd\u00fcm\u00fczle; hastalar\u0131n \u00f6nceliklerine ve ihtiya\u00e7lar\u0131na uygun ila\u00e7lar ve a\u015f\u0131lar \u00fcretece\u011fimize, sivil toplum \u00f6rg\u00fctleri ile i\u015f birli\u011fi yaparak \u00e7al\u0131\u015fmalar\u0131m\u0131zda hasta deneyimlerini \u00f6n planda tutaca\u011f\u0131m\u0131za, ila\u00e7lar\u0131m\u0131z\u0131 ve a\u015f\u0131lar\u0131m\u0131z\u0131 hasta ve sa\u011fl\u0131k kurulu\u015flar\u0131n\u0131n geri bildirimleriyle geli\u015ftirece\u011fimize ve hasta merkezli sa\u011fl\u0131k sistemlerini hayata ge\u00e7irmek i\u00e7in \u00e7al\u0131\u015fmaya devam edece\u011fimize dair s\u00f6z veriyoruz.<\/p>\n\n\n\n

Bu s\u00f6z\u00fcm\u00fcze uygun olarak hasta derneklerinin kurumsalla\u015fma yolculu\u011funda kapasite geli\u015fimine destek olmak amac\u0131yla ROTA e\u011fitim program\u0131n\u0131 ba\u015flatt\u0131k. Amac\u0131m\u0131z, hasta derneklerinin ihtiya\u00e7lar\u0131n\u0131 dinlemek, anlamak, ger\u00e7ek hasta beklentileri \u00fczerinden kamu-\u00f6zel sekt\u00f6r-hasta dernekleri birlikteli\u011fiyle sa\u011fl\u0131k ekosistemine yap\u0131c\u0131 yakla\u015f\u0131mlar sunmak i\u00e7in i\u015f birlikleri geli\u015ftirmek. 2024 y\u0131l\u0131 i\u00e7in de bu yakla\u015f\u0131m\u0131m\u0131z\u0131 daha da ileriye ta\u015f\u0131yacak \u00e7al\u0131\u015fmalar ve i\u015f birliklerine imza atmay\u0131 hedefliyoruz.<\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcrkiye\u2019de 65 y\u0131ldan fazla s\u00fcredir \u00f6zellikli tedaviler, genel ila\u00e7lar, a\u015f\u0131lar ve t\u00fcketici sa\u011fl\u0131\u011f\u0131 alanlar\u0131nda halk sa\u011fl\u0131\u011f\u0131 i\u00e7in \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcren Sanofi\u2019nin Kurumsal \u0130li\u015fkiler ve Pazara Eri\u015fim Direkt\u00f6r\u00fc G\u00fcray Karacar, \u00fclkemizde yenilik\u00e7i ila\u00e7lar\u0131n pazar eri\u015fim s\u00fcre\u00e7leri, Sanofi\u2019nin projeleri, inovasyona bak\u0131\u015f a\u00e7\u0131s\u0131 ve 2024 y\u0131l\u0131 planlar\u0131na ili\u015fkin sorular\u0131m\u0131z\u0131 yan\u0131tlad\u0131.<\/p>\n","protected":false},"author":1,"featured_media":2633,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2632"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2632"}],"version-history":[{"count":3,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2632\/revisions"}],"predecessor-version":[{"id":2641,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2632\/revisions\/2641"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/2633"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}